Following androgen ablation for the treatment of prostatic cancer, any initial positive response is almost universally followed by a relapse to a hormone independent state (Menom & Walsh, 1979) . Treatment of such relapsed tumours by chemotherapy is limited by the toxicity of the agents used, and thus the targeting of such drugs to the tumour site may provide a potentially more effective therapy for hormone independent tumours, with fewer side-effects.
Antibodies have been suggested as potential carriers for drugs (Ghose & Blair, 1978) and methods of linking the drug methotrexate to antisera while retaining both antibody and drug activity have been documented (Kulkarni et al., 1981) . In cultures of the prostate cell line LNCaP, incubation with a monoclonal antiserum to human prostatic acid phosphatase (PAP) linked to methotrexate has been shown to be more effective than a similar conjugate in which the antiserum was substituted by non-immune IgG (Deguchi et al., 1986) .
Using this same conjugate in vivo on LNCaP tumours in athymic nude mice, however, demonstrated that although MTX from the conjugate accumulated more in the tumour than free drug, accumulation was also higher in the spleen, kidney and liver (Deguchi et al., 1986) , which are known sites of MTX toxicity. As PAP from the prostate tumour can be released into the circulation, it is probable that immune complexes form between the antibody in the conjugate and circulating PAP and are taken up by the reticuloendothelial system. Antisera raised against an antigen such as a tumour cell membrane should provide a preferential localisation at the tumour site and thus reduce complex formation within the circulation. This study was therefore undertaken to assess the effectiveness of a cytotoxic drug, methotrexate, conjugated to an antiserum raised against cell membranes isolated from a human prostate cancer cell line PC3.
Materials and methods

Chemicals and reagents
Methotrexate (sodium salt) was purchased from Lederle Laboratories (Hampshire, UK) and MTX (free carboxylic acid), NADPH, dihydrofolate reductase, dihydrofolic acid and NN'-dicyclohexylcarbodiimide (DCC) were purchased from Sigma Chemical Co. Ltd (Dorset, UK). 'H-MTX (250 mCi-(9.25 GBq) mmol-') and 5"Cr GBq) mg-') were products of Amersham International plc (Buckinghamshire, UK). N-Hydroxysuccinimide (NHS) was supplied by Aldrich Chemical Company Ltd (Dorset, UK) and AH Sepharose 4B was obtained from Pharmacia Ltd (Uppsala, Sweden). Diethylaminoethyl cellulose (DE-52) was purchased from Whatman Ltd (Maidstone, Kent, UK) and dust-free Isoton supplied by Coulter Electronics Ltd (Luton, UK). Both Soluene-100 and Dimilume-30 were purchased from United Technologies (Packard, Berks., UK) and microtitre strips obtained from Costar Corporation Ltd (Cambridge, UK). All tissue culture dishes and plates were supplied by Becton-Dickinson UK Ltd (London).
PC3 cell line in vitro and in vivo Athymic nude mice were routinely bred from Nu/Nu males and heterozygous Nu' females and housed in polycarbonate filter-top cages. Irradiated breeding diet (Pilsbury's Ltd, Birmingham, UK) and acidified water (pH 2.8) were given ad libitum. Controlled light and temperature conditions were maintained with a 12 h light/dark cycle and a temperature of 20-22°C.
The human prostate cell line PC3 (Kaighn et al., 1979) was maintained in Dulbecco's modified Eagles medium (DME) supplemented with fetal calf serum (7% v/v), penicillin (200 IU ml'), streptomycin (100 jig ml1), fungizone (5 ,.gml-') and glutamine (1.46 mg ml-'). Cultured PC3 cells required for implantation were trypsinised (trypsin 0.025%; versene 0.02%, v/v) and resuspended in phosphate buffered saline (PBS). The cells were injected subcutaneously into the flanks of 6-8-week-old mice (106 cells per site) and tumours appeared 2-3 weeks later.
(as assessed by the Bio-Rad protein assay) was injected intradermally with Freund's complete adjuvant into New Zealand white rabbits according to the multiple site injection technique described by Vaitukaitis et al. (1971) . The rabbits were boosted with the same amount of immunogen at monthly intervals and blood samples (20 ml) obtained at 14-day intervals by incision of the marginal ear vein.
IgG fractions were obtained from both immune and nonimmune sera by ammonium sulphate precipitation (45% saturation) followed by ion-exchange chromatography on DE-52 by the method described by Fahey and Terry (1973) , in which the IgG fraction was eluted from the column by 0.005 M phosphate buffer (pH 7.4). The specificity of the antiserum was assessed by immunocytochemical techniques on 5;Lm sections of various rat, mouse and human tissues using the unlabelled antibody enzyme method developed by Sternberger et al. (1970) and an adapted protocol reported previously (Sibley et al., 1984 Kulkarni et al. (1981) . MTX (30 mg) was dissolved in dimethylformamide (DMF, 0.4 ml) and added to N-hydroxysuccinimide (15.21 mg per 0.1 ml DMF) and NN'-dicyclohexylcarbodiimide (27.26 mg per 0.1 ml DMF). The reaction mixture was allowed to stand at room temperature for 1 h followed by 18 h at 4°C in the dark. The resulting precipitate was removed by centrifugation (10,000g for 10 min) and the supernatant containing the active ester was stored at 40C in the dark. Determination of the amount of active ester produced was carried out using the method described by Kulkarni et al. (1981) Inhibition of dihydrofolate reductase activity by Ab-MTX conjugates Pharmacological activity of MTX in the conjugate was assessed by its ability to inhibit the enzymatic activity of dihydrofolate reductase (DHFR) and measured spectrophotometrically using the method described by Falk et al. (1976) . MTX standards and Ab-MTX conjugates (2 x 10-8 to 3 x 10-7 M) were incubated separately with the enzyme (0.1 units ml-) at room temperature for 15 min to allow the MTX to bind to the enzyme. Dihydrofolic acid (50 jil of 0.25 mg ml-') was added to each tube and the absorbence measured spectrophotometrically, at 340 nm, after 6 min.
Inhibition of DHFR activity was calculated using the following formula: ', 4, ug MTXml ') in DME, or DME alone (control) for 2 h at 37°C, using quadruplicate cultures per experimental group. After this time medium was aspirated from the wells, the cultures washed with PBS (5 x 2ml), fresh medium (1 ml) added to each well and the cultures incubated for 72 h at 37C. Cells were counted at the end of this period by disrupting the monolayers with trypsin/EDTA and diluting the cells with Isoton (15 ml). The suspended cells were counted on a Coulter counter (model ZB1) equipped with a multichannel analyser facility and an x-y plotter. Total cell population per well was determined by taking account of machine coincidence error, sample volume and dilution of the suspension. Any accumulation of cells within a certain phase of the cell cycle was determined by analysis of the cell size distribution of each experimental group using the multichannel analyser.
Release of 5"Cr from pre-loaded cells Release of 5"Cr from pre-loaded PC3 cells was measured by a modification of the method described by Wigzell (1965) , and gives an estimation of cell death. PC3 cells were seeded onto 24-well plates, at a density of 5 x 103 cells ml' and allowed to recover from trypsinisation for 24 h at 37°C. Pre-labelling of the cells was carried out by the addition of 51Cr in DME (20 fsCi (Table I) . The immunoglobulin fraction used in this study was not completely specific for prostatic tissue as assessed by immunocytochemical techniques. At an antibody dilution of 1/500 (PBS, pH 7.5), human breast, bladder, kidney and intestinal epithelium also exhibited some staining although with a much lower intensity than that observed with benign and carcinomatous prostatic tissue. Staining was always associated with the epithelial cell membrane and no cross-reactivity was observed with any mouse or rat tissues. When equivalent concentrations of Ab and Ab-MTX conjugates were compared in the immunocytochemical procedure, no diminution in membrane staining or change in tissue specificity of the antibody was observed after conjugation (data not shown).
Comparison of free MTX and Ab-MTX conjugates to inhibit the enzyme activity of DHFR indicated that the MTX within the conjugate retained approximately 68% of its ability to bind to the enzyme at a drug concentration of 3 x 10-7 M (Figure 1 ).
Cytotoxicity testing in vitro Cytotoxicity testing was carried out using cultured PC3 cells, each experiment being carried out at least three times. Conjugate and drug concentrations were adjusted to 4 jLg MTX ml-' unless otherwise stated, and antibody concentra- Significantly larger cell numbers were observed (P <0.05) when the PC3 cells incubated with NIgG-MTX conjugates were compared to cells treated with Ab-MTX conjugates. The addition of membrane Ab alone to cultured cells led to a reduction in cell number compared to controls (P<0.05). Cultures incubated with Ab plus MTX, combined but not conjugated, however, displayed a larger cell population than incubation with MTX alone (P<0.05).
Cell size distribution As the inhibition of DHFR leads to inhibition of DNA, RNA and protein synthesis (Bertino, 1963) , cells treated with MTX would be expected to be in Figure 3a and cells treated with Ab alone had an identical profile (Figure 3b) . Incubation of the cells with NIgG-MTX conjugates showed a slight shift towards a larger cell volume (Figure 3b ), whereas cultures treated with either MTX alone (4 gg ml-', Figure 3a) or Ab-MTX conjugates ( Figure 3b ) displayed a pronounced shift towards larger cell volumes indicating an accumulation of cells in the S phase of the cell cycle for these latter two treatments.
The release of 5'Cr from pre-loaded cells The release of "1Cr into the medium from pre-loaded PC3 cells incubated with the various drug concentrations and conjugate are shown in Figure 4 
Discussion
To maintain therapeutic effectiveness of cytotoxic drug linked to antibodies, conjugation should not lead to a substantial loss in either drug activity or in antibody binding and specificity. Therefore, in this present study the resulting conjugation of methotrexate with a polyclonal antiserum raised against a prostatic tumour cell line PC3 was assessed in several systems which examined both the drugs cytotoxic ability in vitro and in vivo and the localisation in vivo.
The retention of antibody activity after conjugation with Table II Tumour and tissue Athymic nude mice bearing palpable PC3 tumours (0.3 -1.1 cm diameter) were injected with MTX, Ab + MTX conjugates, NIgG-MTX conjugates or Ab + MTX every 48 h over a period of 12 days. Each dose of MTX was adjusted to I mg kg-' body weight (22 1sg per animal in 100 !Ll saline) and the concentration of Ab given to control animals adjusted to the equivalent amount in the Ab-MTX conjugate (498 fg per animal in 100 gul saline). Animals were bled by cardiac puncture 2 h after the last injection, killed and the various body tissues removed. Tissues (up to 100 mg wet weight) were solubilised with Soluene (1 ml) and the amount of 3H label measured by scintillation counting. Quench correction was carried out by internal standardisation and the total amount of MTX present calculated with reference to the original starting material (4.2 uCi(O. 155 MBq) mg-'). Data are expressed as ng MTX per g wet weight oftissue each value representing the mean from five experimental animals. Tissue: blood ratios are given in parentheses.
the least interruption in structure and activity is clearly of major importance, excess drug linkage or adverse reaction conditions leading to denaturation or aggregation of the antibody. In (Deguchi et al., 1986; Fung et al., 1979; Garnett et al., 1983; Kanellos et al., 1985; Kulkarni et al., 1985; Tsuro et al., 1980) and is probably due to the stearic interference of the macromolecule with the binding of the pteridine moiety of the methotrexate to the active site of the enzyme (Baker, 1969 (Bertino, 1963) (Hurwitz et al., 1979; Johnson et al., 1981; Kulkarni et al., 1985) . In the experiments reported in this paper, non-immune IgG-methotrexate conjugates were significantly less effective than either methotrexate alone or antibody-methotrexate conjugates in reducing the cell number ( Figure 2 ) and causing in the release of 5'Cr from cells in vitro (Figure 4) . Furthermore, these non-immune conjugates did not significantly reduce tumour growth in vivo ( Figure 5 ). Analysis of cell size distribution after incubation of the PC3 cells with the various drugs and conjugates demonstrated that the non-immune methotrexate conjugates failed to display the same distribution profile observed with free drug or antibody-methotrexate conjugates (Figure 3 ).
Assuming that both immunoglobulin conjugates are broken down within the cell in the same manner, the results would suggest that the non-immune conjugates are unable either to bind or to enter the cell to the same extent. Such nonimmune immunoglobulin conjugates appear to rely upon non-specific uptake by the cell and discrepancies in data from different laboratories may be due to the amount of nonspecific binding regions on the cell surface or the pinocytoic activity of the cell line under study. An altered clearance rate may also contribute to differences found in vivo.
Specific antibody-methotrexate conjugates have been reported to enter the cell as a consequence of antibody binding and subsequent endocytosis (Smyth et al., 1987) rather than via the active carrier-mediated transport system used for methotrexate or by the non-specific uptake of non-immune conjugates. Assessments of the cytotoxic effectiveness of the antibody-methotrexate conjugates in vitro, using measurements of both 5"Cr release from pre-loaded cells (Figure 4) and cell population parameters (Figure 2) (Kulkarni et al., 1981; Lee & Hwang, 1979; Tai et al., 1979) and in some cases an enhanced effect has been observed over the conjugate (Hurwitz et al., 1978) .
No such synergistic effect between drug and antibody could be demonstrated in our study and may be explained by the high affinity of the polyclonal antiserum utilised for the cell membrane. As a carrier mediated active transport system has been reported for methotrexate (Goldman et al., 1968) it is possible that enhanced binding of the antibody to the cell membrane in our study may block this carrier system, thus hampering drug transport. High affinity membrane binding might also explain the cytotoxicity of the antibody when given alone, both in vitro (Figures 2 and 4 ) and in vivo ( Figure 5 ). Antibody cytotoxicity is well documented (Motta, 1971) and antibodies against tumour associated cell surface antigens have been demonstrated to produce membrane mediated cell changes either directly (Yang & Vas, 1970) or through complement and other intermediaries both in vitro and in vivo (Ghose et al., 1977) .
When anti-membrane antibody-methotrexate conjugates were given to nude mice bearing PC3 tumours, a highly significant reduction in tumour growth was observed when compared to all other treatment groups ( Figure 5 ). The concentration of 3H-methotrexate in the tumours of animals given these conjugates were significantly higher than controls (P<0.01 in all cases, Table II ). Animals treated with both specific anti-membrane antibody and non-immune antibody conjugates displayed significantly higher blood levels of 3H-methotrexate than animals receiving drug in its free form thus indicating a slower clearance rate. Few studies have involved measurement of the in vivo distribution of cytotoxic drugs linked to antibodies. Deguchi et al. (1986) reported an increase of 3H in the liver and kidney of animals given a conjugate of methotrexate linked to a monoclonal antibody against prostatic acid phosphatase (PAP). As PAP is a secretory product of prostatic cells it is conceivable that its release into the blood stream is sufficient to elicit the formation of antibody complexes, which would then be taken up by the reticuloendothelial system. This may explain the elevated levels of radioactivity labelled conjugate within the liver and kidneys of their animals in comparison to controls. Selection of an antiserum against prostatic cell membranes for conjugation with a cytotoxic drug, in preference to one against secretory products of the cells, should reduce the possibility of antibody complexes forming within the blood. Indeed in our study treatment with the anti-membrane antibody-methotrexate conjugates significantly increased drug accumulation at the tumour site without increasing the level of drug in the other body tissues, suggesting that uptake by the reticuloendothelial system was not pronounced.
Although it would appear that the anti-membrane antibody-methotrexate conjugates described in this study provided an efficient means for specificity targeting the drug in vivo, other anti-membrane antibody conjugates do not appear to produce such significant tumour reduction (Kanellos et al., 1987; Smyth et al., 1986) . As the antibody preparation employed in this study consisted of a purified rabbit polyclonal antiserum to prostate membranes, its effectiveness in vivo may probably relate to the existence of numerous antibodies to various cell surface antigens. A cocktail of three monoclonal antibodies against the surface of T lymphocytes, linked to the toxin ricin, was found to be more effective in inhibiting T cell proliferation than any single monoclonal antibody (Vallers et al., 1983) . The approach of using a battery of antibodies against various antigenic determinants on the cell membrane may therefore provide a more efficient carrier system for drug targeting.
The polyclonal antibody used in this study was, as stated, not specific for its prostate cell target and we are fully aware of the need for a battery of anti-membrane monoclonals preferential to human prostatic epithelial cells for future targeting and clinical studies.
